Menu
Back to Journals » Drug Design, Development and Therapy » Volume 13
Efficacy of a recombinant single-chain fragment variable region, VasSF, as a new drug for vasculitis [Corrigendum]
Authors Kameoka Y, Kishi F, Koura M, Yamakawa Y, Nagasawa R, Ito F, Matsuda J, Suzuki O, Nakayama T, Suzuki K
Received 12 April 2019
Accepted for publication 12 April 2019
Published 22 May 2019 Volume 2019:13 Pages 1689—1690
Kameoka Y, Kishi F, Koura M, et al. Drug Des Devel Ther. 2019;13:555–568.
The authors have advised that there was an error in the text.
Page 561, beginning at the left-hand bottom of the page, “The number of peripheral blood lymphocytes and granulocytes did not change in the aVAP2-administered mice: WBCs: 4.42 (1.36–7.57)×109 cells/L vs 3.14 (1.48–15.7)×109 cells/L (Figure S3A). The number of granulocytes decreased: 0.15 (0.05–1.04)×109 cells/L vs 0.22 (0.04 0.69)×109 cells/L (Figure S3B).” should instead read “The number of peripheral blood lymphocytes and granulocytes did not change in the aVAP2-administered mice: WBCs: 2.11 (1.36–2.44)×109 cells/L vs 3.14 (1.48–15.7)×109 cells/L (Figure S3A). The number of granulocytes decreased: 0.055 (0.03–0.08)×109 cells/L vs 0.22 (0.04–0.69)×109 cells/L (Figure S3B).”
© 2019 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.